Light Chain Amyloidosis clinical trials

Explore recruiting light chain amyloidosis clinical trials.

Recruiting light chain amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Light Chain Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis

Greece, France, Italy

Phase I and Phase II (Integrated)- Bioequivalence Study EU CTIS Study details

A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

Spain, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Germany, France, Spain, Netherlands, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone) in Untreated Patients with Light Chain Amyloidosis

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Light Chain Amyloidosis trials by city

Light Chain Amyloidosis in Toronto Light Chain Amyloidosis in Vancouver Light Chain Amyloidosis in Montreal Light Chain Amyloidosis in Calgary Light Chain Amyloidosis in Edmonton Light Chain Amyloidosis in Ottawa Light Chain Amyloidosis in Winnipeg Light Chain Amyloidosis in Quebec City Light Chain Amyloidosis in Hamilton Light Chain Amyloidosis in Kitchener Light Chain Amyloidosis in London Light Chain Amyloidosis in Halifax Light Chain Amyloidosis in New York Light Chain Amyloidosis in Los Angeles Light Chain Amyloidosis in Chicago Light Chain Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease